These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27676409)

  • 1. Time in Therapeutic Range for Left Ventricular Assist Device Patients Anticoagulated With Warfarin: A Correlation to Clinical Outcomes.
    Halder LC; Richardson LB; Garberich RF; Zimbwa P; Bennett MK
    ASAIO J; 2017; 63(1):37-40. PubMed ID: 27676409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center.
    Bishop MA; Streiff MB; Ensor CR; Tedford RJ; Russell SD; Ross PA
    ASAIO J; 2014; 60(2):193-8. PubMed ID: 24577370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of Time in Therapeutic Range in Continuous-Flow Left Ventricular Assist Device Patients Receiving Warfarin.
    Martinez BK; Yik B; Tran R; Ilham S; Coleman CI; Jennings DL; Baker WL
    Artif Organs; 2018 Jul; 42(7):700-704. PubMed ID: 29508409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices.
    Nassif ME; LaRue SJ; Raymer DS; Novak E; Vader JM; Ewald GA; Gage BF
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27154497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Time in Therapeutic Range with International Normalized Ratio Remote Monitoring for Patients with Left Ventricular Assist Devices.
    Nguyen VN; Stevens CA; Brambatti M; Smith M; Braun OO; Mariski M; Pretorius VG; Adler ED; Feist AA
    ASAIO J; 2022 Mar; 68(3):363-368. PubMed ID: 34225278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device.
    Henderson JB; Iyer P; Coniglio AC; Katz JN; Chien C; Hollis IB
    Pharmacotherapy; 2019 Oct; 39(10):1030-1035. PubMed ID: 31463945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.
    Saeed O; Shah A; Kargoli F; Madan S; Levin AP; Patel SR; Jermyn R; Guerrero C; Nguyen J; Sims DB; Shin J; D'Alessandro D; Goldstein DJ; Jorde UP
    Circ Heart Fail; 2016 Jan; 9(1):e002296. PubMed ID: 26721914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating warfarin management by pharmacists in a community teaching hospital.
    Chilipko AA; Norwood DK
    Consult Pharm; 2014 Feb; 29(2):95-103. PubMed ID: 24513419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods.
    Lea JC; Floroff CK; Ingemi AI; Zeevi GR
    J Thromb Thrombolysis; 2019 Apr; 47(3):361-368. PubMed ID: 30739304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
    Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
    J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Initial Warfarin Dosing on Time in Therapeutic Range for Postoperative Left Ventricular Assist Device Patients.
    Olson LM; Korkames GC; Lyden ER; Ryan TR; Bowman SA
    J Cardiovasc Pharmacol; 2022 Sep; 80(3):471-475. PubMed ID: 35881901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor.
    Vanerio G
    J Stroke Cerebrovasc Dis; 2015 Oct; 24(10):2223-8. PubMed ID: 26232891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device.
    Stulak JM; Lee D; Haft JW; Romano MA; Cowger JA; Park SJ; Aaronson KD; Pagani FD
    J Heart Lung Transplant; 2014 Jan; 33(1):60-4. PubMed ID: 24021944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device.
    Van Tuyl JS; Hollis IB; Alburikan KA; Tran RH; Murray BP; Rodgers JE; Katz JN; Sheridan BC
    ASAIO J; 2017; 63(6):731-735. PubMed ID: 28319521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of anticoagulation and nonsurgical major bleeding in recipients of continuous-flow left ventricular assist devices.
    Veasey TM; Floroff CK; Strout SE; McElray KL; Brisco-Bacik MA; Cook JL; Toole JM; Craig ML; Van Bakel AB; Meadows HB; Uber WE
    Artif Organs; 2019 Aug; 43(8):736-744. PubMed ID: 30868618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.
    Bernard AM; Alvarez PA; Bream-Rouwenhorst HR; Horner KE; Briasoulis A; Czerniak LC
    J Pharm Pract; 2022 Jun; 35(3):422-426. PubMed ID: 33648405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices.
    Santos CD; Matos NL; Asleh R; Dawit S; Rabinstein AA; O'Carroll CB; Li Z; Freeman WD
    Neurocrit Care; 2020 Jun; 32(3):822-827. PubMed ID: 31531758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.